Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Elucid secures $55 million in an oversubscribed Series D financing led by a large medtech company. This round aims to enhance AI-powered technology for cardiovascular diagnosis and treatment.
PRIVATESep 02, 2026•6 days ago
Amount Raised
$55 Million
Round Type
Series D
BostonManufacturingHealth Care
Description
Elucid, a medical technology company, has raised $55 million in an oversubscribed Series D financing. This round includes new participation from a significant medtech company, marking it as Elucid’s fourth publicly-traded strategic investor. The funds will further advance their AI-powered software for precision diagnosis and treatment of cardiovascular disease. The total funding raised by Elucid to date is approximately $185 million.
Company Information
Company
Elucid
Location
Boston, Massachusetts, United States
About
Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.
Don't miss Elucid's next move
Get an email the moment Elucid raises, hires an exec, or expands, usually minutes after it happens.
BostonManufacturingHealth Care